Ph1 Clinical proof of Mechanism for NextGen pre|CISION® platform
Initial data for AVA6103 demonstrate proof of mechanism with two key findings from the clinical trial:
-
AVA6103 pre|CISION® controlled-release exatecan shows clean safety profile through first 3 dose levels
-
PK profile as expected based on predictive PK modeling from preclinical studies